News

Call for Abstracts to Present at MHSRS 2021

The call for abstracts to present a poster at this year’s Military Health System Research Symposium (MHSRS) is now open through March 31. They are planning for this year’s conference to be in person. The dates are pending, but usually are in mid- to late-August in Orlando, FL. G2G account managers will reach out separately and in your next check-in call re: assisting with a submission. Details below.

NOTE: DoD-sponsored SARS CoV-2 (COVID-19) related research will be highlighted in dedicated 2021 MHSRS breakout sessions. Oral presentations at these sessions will be by invitation only.

* The Call for Abstracts will be for posters only. COVID-19 related research abstracts submitted to sessions other that those that are focused on COVID-19 will be re-directed to the COVID-19 session leads for poster consideration.

* For 2021, a special MHSRS award category for COVID-19 research will be offered for individuals and teams.

2021 MHSRS Call for Abstracts
February 17, 2021 to March 31, 2021
The deadline will not be extended past 31 March 2021.

How to Submit a 2021 Abstract
(1) Complete the abstract submission form, (2) upload a CV, (3) upload a signed Conflict of Interest (COI) form

The abstract should be no more than 8000 characters in length. There are no format or font restrictions. No embedded tables, pictures, or videos will be accepted. Have the presenter CV and signed COI form in pdf format ready to upload when you initiate abstract submission to facilitate the submission process.

Link to submit and Abstract: https://mhsrs.amedd.army.mil/SitePages/Submit-an-Abstract.aspx

Recent News

10/16/2026

Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”), which recently acquired Azora Therapeutics, today announced the appointment of David Rubenstein, M.D., Ph.D. as Chief Scientist. Dr. Rubenstein will lead the Company’s research and scientific strategy, including the continued development of AT177, a proprietary, oral, colon-targeted aryl hydrocarbon receptor (AhR) agonist being developed for the …

10/13/2026

ISOThrive Final Phase 2 Results for MHS-1031 Announced at ACG 2026 Demonstrate Statistically Significant and Clinically Meaningful Improvement in Heartburn Frequency and Severity in NERD PPI-Partial Responders

ISOThrive Inc. announced final results from its Phase 2 trial of MHS-1031 in patients with non-erosive reflux disease (NERD) who experience an incomplete response to proton pump inhibitors (PPIs). Peter Swann, MD, Chief Medical Officer of ISOThrive, and David Johnson, MD MACG FASGE VGSF MACP, Professor of Medicine and Chief of Gastroenterology at Eastern Va …

10/13/2026

Virginia Western and Radford University sign 3 new agreements to create seamless transfer for medical laboratory science degree

Virginia Western Community College and Radford University celebrated a strengthened partnership on Monday, Oct. 12, that will enable seamless transfer for students in three health-related programs. Virginia Western President Laura J. Treanor and Radford President Bret Danilowicz signed the articulation agreements in a ceremony on the Virginia Western campus. Virginia Western students who meet all requirements and complete …